Literature DB >> 3591613

Adriamycin cardiotoxicity and proton nuclear magnetic resonance relaxation properties.

R C Thompson, R C Canby, E W Lojeski, A V Ratner, J T Fallon, G M Pohost.   

Abstract

Present noninvasive techniques to detect Adriamycin (doxorubicin) cardiotoxicity rely on assessment of myocardial function rather than direct observation of change in tissue character. Proton nuclear magnetic resonance imaging may provide a unique means of characterizing the myocardium. The relaxation properties T1 and T2 are related to certain biophysical properties of tissue such as water, lipid, and macromolecular content and have considerable impact on the intensity observed in nuclear magnetic resonance images. In a model of chronic Adriamycin cardiotoxicity in rats, T1 values of excised hearts were elevated, relative to control, in rats with histologic evidence of chronic cardiotoxicity (651 msec vs 622 msec, p less than 0.05) and more so in rats with gross evidence of toxicity or heart failure (668 msec, p less than 0.005). No significant change in T2 was observed. This T1 prolongation increases as disease worsens, whereas water concentration did not change significantly. The results suggest that predictable prolongation in T1 occurs in association with cardiotoxicity. In conclusion, proton nuclear magnetic resonance imaging methods could provide a new means for assessing Adriamycin cardiotoxicity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3591613     DOI: 10.1016/0002-8703(87)90660-0

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  8 in total

1.  Diastolic or systolic left and right ventricular impairment at moderate doses of anthracycline? A 1-year follow-up study of women.

Authors:  Y Cottin; C Touzery; B Coudert; S Richebourg; M Cohen; M Toubeau; P Louis; J E Wolf; F Brunotte
Journal:  Eur J Nucl Med       Date:  1996-05

2.  Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental model.

Authors:  James C Lightfoot; Ralph B D'Agostino; Craig A Hamilton; Jennifer Jordan; Frank M Torti; Nancy D Kock; James Jordan; Susan Workman; W Gregory Hundley
Journal:  Circ Cardiovasc Imaging       Date:  2010-07-09       Impact factor: 7.792

3.  Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic resonance.

Authors:  Jennifer H Jordan; Ralph B D'Agostino; Craig A Hamilton; Sujethra Vasu; Michael E Hall; Dalane W Kitzman; Vinay Thohan; Julia A Lawrence; Leslie R Ellis; Timothy L Lash; W Gregory Hundley
Journal:  Circ Cardiovasc Imaging       Date:  2014-10-01       Impact factor: 7.792

4.  Impairment of diastolic function during short-term anthracycline chemotherapy.

Authors:  Y Cottin; C Touzery; B Coudert; A Gilles; P Walker; J L Massing; M Toubeau; A Riedinger-Berriolo; D Caillot; P Louis
Journal:  Br Heart J       Date:  1995-01

Review 5.  Cardiac 1H MR spectroscopy: development of the past five decades and future perspectives.

Authors:  Ashish Gupta; Brian Houston
Journal:  Heart Fail Rev       Date:  2021-01-07       Impact factor: 4.214

Review 6.  Understanding cardiovascular injury after treatment for cancer: an overview of current uses and future directions of cardiovascular magnetic resonance.

Authors:  Sujethra Vasu; W Gregory Hundley
Journal:  J Cardiovasc Magn Reson       Date:  2013-07-31       Impact factor: 5.364

Review 7.  MRI of Cardiotoxicity.

Authors:  Jennifer Hawthorne Jordan; William Gregory Hundley
Journal:  Cardiol Clin       Date:  2019-08-31       Impact factor: 2.410

Review 8.  Cardiovascular Magnetic Resonance in the Oncology Patient.

Authors:  Jennifer H Jordan; Ryan M Todd; Sujethra Vasu; W Gregory Hundley
Journal:  JACC Cardiovasc Imaging       Date:  2018-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.